Myriam  Curet net worth and biography

Myriam Curet Biography and Net Worth

Director of Nektar Therapeutics
Dr. Myriam J. Curet has served as a Nektar Director since December 2019. Dr. Curet has three decades of experience working in the healthcare sector and academia, and currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, Inc., a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery.

Dr. Curet joined Intuitive Surgical in 2005 and has held several leadership positions of increasing responsibility. Previously, she served as Chief Medical Advisor and Senior Vice President, Chief Medical Officer. Since 2000, she has also held a faculty position at Stanford University School of Medicine, serving as a Clinical Professor of Surgery with a part-time clinical appointment at the Veteran's Administration Medical Center in Palo Alto, California. Prior to joining Stanford, she served as Associate Professor of Surgery at the University of New Mexico. Earlier, she held various positions at the Indian Health Service, an agency within the Department of Health and Human Services (HHS). Dr. Curet began her career in medicine at the Gallup Indian Medical Center in New Mexico, where she was Medical Deputy Director. Dr. Curet holds a B.A. degree from Bryn Mawr College and an M.D. from Harvard Medical School. She completed a residency in general surgery at the University of Chicago and a fellowship in surgical endoscopy at the University of New Mexico.

What is Myriam Curet's net worth?

The estimated net worth of Myriam Curet is at least $393.36 as of March 1st, 2024. Dr. Curet owns 298 shares of Nektar Therapeutics stock worth more than $393 as of April 18th. This net worth evaluation does not reflect any other investments that Dr. Curet may own. Learn More about Myriam Curet's net worth.

How do I contact Myriam Curet?

The corporate mailing address for Dr. Curet and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on Myriam Curet's contact information.

Has Myriam Curet been buying or selling shares of Nektar Therapeutics?

Myriam Curet has not been actively trading shares of Nektar Therapeutics in the last ninety days. Most recently, Myriam Curet sold 4,359 shares of the business's stock in a transaction on Monday, September 18th. The shares were sold at an average price of $0.69, for a transaction totalling $3,007.71. Following the completion of the sale, the director now directly owns 27,418 shares of the company's stock, valued at $18,918.42. Learn More on Myriam Curet's trading history.

Who are Nektar Therapeutics' active insiders?

Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.

Are insiders buying or selling shares of Nektar Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 152,782 shares worth more than $99,202.16. The most recent insider tranaction occured on February, 20th when insider Jonathan Zalevsky sold 9,014 shares worth more than $6,129.52. Insiders at Nektar Therapeutics own 3.1% of the company. Learn More about insider trades at Nektar Therapeutics.

Information on this page was last updated on 2/20/2024.

Myriam Curet Insider Trading History at Nektar Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/18/2023Sell4,359$0.69$3,007.7127,418View SEC Filing Icon  
9/23/2022Sell4,198$3.16$13,265.6831,777View SEC Filing Icon  
9/22/2021Sell3,665$17.78$65,163.70View SEC Filing Icon  
See Full Table

Myriam Curet Buying and Selling Activity at Nektar Therapeutics

This chart shows Myriam Curet's buying and selling at Nektar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nektar Therapeutics Company Overview

Nektar Therapeutics logo
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $1.32
Low: $1.27
High: $1.36

50 Day Range

MA: $0.94
Low: $0.66
High: $1.67

2 Week Range

Now: $1.32
Low: $0.41
High: $1.75

Volume

3,575,769 shs

Average Volume

2,163,717 shs

Market Capitalization

$242.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9